Published in Support Care Cancer on November 28, 2013
Eribulin in Brain Metastases From HER2-negative Breast Cancer (ERIBRAIN) | NCT03637868
Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res (2016) 0.81
Exercise preferences and associations between fitness parameters, physical activity, and quality of life in high-grade glioma patients. Support Care Cancer (2016) 0.75
Sleep-wake disturbance in patients with brain tumors. Neuro Oncol (2016) 0.75
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care (2007) 12.71
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol (2009) 10.43
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain (2007) 8.89
Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell (2008) 7.47
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64
Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol (2007) 6.24
Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med (2008) 5.92
Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med (2002) 5.69
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes (2003) 5.58
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol (2011) 5.43
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol (2002) 4.69
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26
Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger. Assessment (2011) 4.21
Representativeness of the Patient-Reported Outcomes Measurement Information System Internet panel. J Clin Epidemiol (2010) 4.18
Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol (2002) 4.16
Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res (2009) 4.13
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (2004) 3.85
Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health (2008) 3.68
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes (2007) 3.66
Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol (2012) 3.65
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys (2011) 3.63
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol (2004) 3.57
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol (2013) 3.48
A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof (2005) 3.43
Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol (2007) 3.24
Assessment of neurological and behavioural function: the NIH Toolbox. Lancet Neurol (2010) 3.20
Item response theory analyses of physical functioning items in the medical outcomes study. Med Care (2007) 3.10
Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol (2005) 2.98
Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol (2007) 2.97
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol (2013) 2.90
Development of a PROMIS item bank to measure pain interference. Pain (2010) 2.85
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol (2009) 2.82
FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet (2012) 2.74
Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells (2009) 2.71
Efficiency of static and computer adaptive short forms compared to full-length measures of depressive symptoms. Qual Life Res (2009) 2.55
General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof (2005) 2.51
Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol (2008) 2.50
Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes (2006) 2.48
Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain (2007) 2.47
Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors. Int J Radiat Oncol Biol Phys (2012) 2.45
Duration of colonization with methicillin-resistant Staphylococcus aureus. Clin Infect Dis (2009) 2.42
Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology Group. J Clin Oncol (2003) 2.41
Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. J Rheumatol (2009) 2.39
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol (2008) 2.34
Autosis is a Na+,K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc Natl Acad Sci U S A (2013) 2.33
Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create a core item bank from the FACIT-Fatigue Scale. Qual Life Res (2003) 2.32
Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol (2005) 2.27
Association between a high number of isolated lymph nodes in T1 to T4 N0M0 colorectal cancer and the microsatellite instability phenotype. Arch Surg (2010) 2.26
Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol (2011) 2.24
Evaluating equivalency between response systems: application of the Rasch model to a 3-level and 5-level EQ-5D. Med Care (2007) 2.22
Granzyme B is critical for T cell receptor-induced cell death of type 2 helper T cells. Immunity (2006) 2.21
Development of the European Organisation for Research and Treatment of Cancer quality of life questionnaire module for older people with cancer: The EORTC QLQ-ELD15. Eur J Cancer (2010) 2.20
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst (2002) 2.19
Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol (2010) 2.19
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer (2002) 2.17
A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol (2004) 2.14
Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol (2010) 2.12
Predicting EuroQol (EQ-5D) scores from the patient-reported outcomes measurement information system (PROMIS) global items and domain item banks in a United States sample. Qual Life Res (2009) 2.10
Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol (2009) 2.08
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res (2012) 2.04
Palliative care and oncology: integration leads to better care. Oncology (Williston Park) (2011) 2.02
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med (2007) 2.00
Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res (2011) 1.97
CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell (2012) 1.97
ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res (2013) 1.96
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol (2004) 1.95
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res (2006) 1.94
Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol (2005) 1.93
HIV-testing behavior among young migrant men who have sex with men (MSM) in Beijing, China. AIDS Care (2011) 1.93
Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. Support Care Cancer (2008) 1.89
Transforming growth factor beta is dispensable for the molecular orchestration of Th17 cell differentiation. J Exp Med (2009) 1.89
Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 1.88
Issues in the development of an item bank. Arch Phys Med Rehabil (2003) 1.87
The use of PROMIS and assessment center to deliver patient-reported outcome measures in clinical research. J Appl Meas (2010) 1.87
Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care (2007) 1.87
Topical therapy for methicillin-resistant Staphylococcus aureus colonization: impact on infection risk. Infect Control Hosp Epidemiol (2009) 1.83
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev (2012) 1.79
Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa. J Am Geriatr Soc (2007) 1.79
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol (2007) 1.77
Minimal clinically important differences in the Edmonton symptom assessment system in patients with advanced cancer. J Pain Symptom Manage (2012) 1.76